Published in final edited form as:

J Am Chem Soc. 2013 March 20; 135(11): 4231–4234. doi:10.1021/ja401423j.

Enantioselective Total Synthesis of Plectosphaeroic Acid B

Salman Y. Jabri and Larry E. Overman*

Department of Chemistry, 1102 Natural Sciences II, University of California, Irvine, California 92697-2025

Abstract

The first total synthesis of a member of the plectosphaeroic acid family of fungal natural products is reported. Key steps include the late-stage formation of the hindered N6–C9'' bond and stereoselective introduction of the two methylthio substituents.

In 2009, Mauk, Andersen and coworkers reported the isolation of plectosphaeroic acids A–C (**1–3**) from cultured extracts of the fungus *Plectosphaerella cucumerina* collected in Barkley Sound, British Columbia (Figure 1).¹ These highly functionalized, secondary metabolites are defined by the union of a tryptophan-derived epitrithiodioxopiperazine (or methylthio analog)² and 2-aminophenoxazin-3-one fragments,³ structural motifs commonly found in natural products but never before seen in conjunction. A number of epipolythiodioxopiperazine (ETP) alkaloids and their methylthio congeners (e.g., **5–11**) share a polycyclic core that is homologous to the northern fragments of **1–3**.^{4,5} Naturally occurring cinnabarinic acid (**4**) comprises the southern fragment of **1–3**. Molecules comprised of either structural motif display a broad spectrum of biological properties (e.g., antimicrobial, antiviral, antifungal, immunosuppressive, and anticancer activities),^{2,3} with numerous studies focusing on chemotherapeutic applications.^{6,7} In the isolation report, it was disclosed that **1–3** were equipotent (IC₅₀ = 2 μM) against indoleamine 2,3-dioxygenase (IDO), a recently identified molecular target for the potential treatment of cancer. Although it was found that only the phenoxazinone subunit is required for this activity,⁸ we were intrigued by the potential utility of molecules that contain both anticancer motifs,⁹ as well as the considerable synthetic challenges^{10–12} posed by the complexity of **1–3**. Herein, we describe our recent efforts that culminated in the first total synthesis of (+)-plectosphaeroic acid B (**2**).

Our plan for preparing plectosphaeroic acids A–C (**1–3**) is outlined in Scheme 1. We envisaged stereoselectively introducing the labile thioethers or bridging trisulfide functionalities of **1–3** after late-stage construction of the critical C9''–N6 bond between the indoline nitrogen atom of fragment **12** and a halogenated congener **13** of cinnabarinic acid. Although efficient transition metal-catalyzed methods are known, the hindered nature and structural complexity of these intermediates would make the successful joining of fragments **12** and **13** one of the most challenging applications of C–N cross-coupling to date.^{13,14} Fragment **12** was seen arising from the simpler trioxopiperazine alkaloid (+)-gliocladin C (**14**)^{4b,4e,10a,15} using a general sequence our group disclosed in 2011 for the total synthesis of the ETP natural product (+)-gliocladin C (**5**).¹⁰ Halide **13** was envisioned originating from the biomimetic, oxidative dimerization of 6-halo-3-hydroxyanthranilic acid **15**.¹⁶

*Corresponding Author: leoverma@uci.edu.

ASSOCIATED CONTENT

Supporting Information. Experimental details, characterization data, copies of ¹H and ¹³C NMR spectra of new compounds, full list of authors for reference 6c, and CIF file for **21a**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

In order to assess the feasibility of—and identify conditions for—the critical C–N bond-forming step, we began our efforts by examining *N*-arylation of a structurally simplified indoline fragment (Scheme 2). The di-(*tert*-butoxycarbonyl) derivative **16** of (+)-gliocladin C, which is available on multi-gram scale by chemical synthesis,^{10a} was exposed to a catalytic amount of Sc(OTf)₃, resulting in the selective deprotection of the indoline nitrogen atom. After a considerable screening effort,¹⁷ joining of the two fragments was realized in 67% yield when indoline **17** was allowed to react with 2.3 equiv of iodide **18**,¹⁸ 3.0 equiv of copper(I) thiophene-2-carboxylate (CuTC)¹⁹ and excess K₂CO₃ in toluene at 90 °C. Other Cu(I) salts and ligand combinations that were screened gave poor conversions to **19** (0–20% yields). Reducing the amount of CuTC also resulted in low yields of **19**. Additionally, it was found that double protection of the 2-amino group of iodide **18** was critical,²⁰ and that *N*-arylation of the corresponding bromide was much less efficient (8% yield of **19**). Although the excess of iodide **18** was recoverable, minor amounts of the by-product arising from undesired hydrodehalogenation of **18** were observed as well. Having discovered conditions to successfully unite the two fragments, we focused our attention on the synthesis of plectosphaeroic acid B (**2**).

The total synthesis of (+)-plectosphaeroic acid B (**2**) commenced with deprotection of the indoline nitrogen atoms of the individual epimers **20a** and **20b**, intermediates previously prepared en route to (+)-gliocladin C (**5**) (Scheme 3).¹⁰ Attempts to chemoselectively remove the Boc group of **20a** or **20b** with Lewis or protic acids proved challenging because of the other acid-labile functionalities that were present, including the C3- and C12-*N,O*-acetals. For this reason, a two-step (single-pot) procedure was developed. Thermolytic cleavage of both Boc groups of **20a** or **20b**, followed by selective reprotection of the indole nitrogen atom by reaction with 1 equiv of Boc₂O and a catalytic amount of DMAP afforded intermediates **21a** and **21b** in 60–80% yields. Complete inversion of the C12-stereocenter occurred during the thermolytic-deprotection step.²¹

The potential to form an *N*-acyliminium ion by loss of the oxygen substituents at C3 or C12 also complicated the ensuing copper-mediated C–N cross-coupling reaction. In preliminary experiments, treatment of epimer **21a** with iodide **18**, CuTC and K₂CO₃ resulted in inefficient conversion to the coupled product **22a** (10–30% yields). In these reactions, some formation of the thiophene-2-carboxylate adduct **23** was observed. As in-situ activation of the angular *N,O*-acetal appeared unavoidable, we explored substituting CuTC with CuOAc²² in order to minimize the formation of by-products. After some optimization, exposure of **21a** or **21b** to 3.0 equiv of iodide **18** and 6.0 equiv of CuOAc in toluene at 90 °C delivered **22a** and **22b** in 50–58% yields.

We turned our attention to the stereoselective installation of the methylthio substituents of **2**.²³ Activation of the *N,O*-acetals of **22a** and **22b** by exposure to excess BF₃·OEt₂ and MeSH in CH₂Cl₂ at –78 °C with slow warming to room temperature led to the generation of a 1.3:1.0 mixture of di(methylthio)ethers **24** and **C3-*epi*-24** in high yield (79% from **22a**, 92% from **22b**). Alternatively, it was found that transforming **22a** or **22b** by reaction with H₂S and BF₃·OEt₂, then methylation with MeI and K₂CO₃, provided *cis*-di(methylthio)ether **24** in 80–90% yield as virtually a single stereoisomer. The difference in stereochemical outcomes for these sulfenylation procedures warrants further comment. Substantial precedent suggests that introduction of the sulfur nucleophile would occur first at C12, with high stereoselectivity from the concave face.^{2c,2e,10,11} The factors governing the facial selectivity of the subsequent addition of the sulfur nucleophiles at C3 are less certain. The greater stereoselectivity we observe in forming **2** by the two-step sequence could reflect the difference between directly forming configurationally stable thioether products or proceeding via configurationally less stable hemithioaminal intermediates, which could be

equilibrating under the sulfonylation or methylation conditions to the more stable *cis* product.^{24–26}

Completion of the synthesis of (+)-plectosphaeroic acid B (**2**) required careful removal of the three remaining ester groups.²⁷ Methanolysis of the C11-acetate of **24** was achieved using excess La(OTf)₃ and 1 equiv of DMAP at 50 °C. Then, conversion of the methyl esters of the phenoxazinone subunit to carboxylic acids by the use of LiI in pyridine at 90 °C gave (+)-plectosphaeroic acid B (**2**) in 65% yield over two steps after HPLC purification. The optical rotation of synthetic **2**, [α]_D²³ +228 (*c* 0.08, MeOH), was considerably higher than the reported value for the natural sample, [α]_D²³ +69.8 (*c* 0.27, MeOH). However, all other spectroscopic data, including CD spectra, compared well.

In conclusion, the first total synthesis of (+)-plectosphaeroic acid B (**2**) was achieved in seven steps from the known intermediates **20a** and **20b**. This total synthesis confirms the unique structure and absolute configuration of plectosphaeroic acid B, which had been assigned on the basis of NMR, MS and CD data.¹ Introduction of the highly congested, central C–N bond of **2** by a late-stage copper-mediated process provides one of the most demanding examples of C–N cross-coupling reported to date. The convergence of this synthesis strategy should enable the synthesis of the remaining plectosphaeroic acids and analogues, and allow the pharmacological evaluation of these and related molecules containing multiple anticancer motifs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Support was provided by the National Institutes of General Medical Sciences of NIH (R01GM-30859). SYJ thanks Eli Lilly and Co. and Bristol-Myers Squibb Co. for graduate fellowships. Computational studies were performed on hardware purchased with funding from CRIF (CHE-0840513). NMR and mass spectra were determined at UC Irvine using instruments purchased with the assistance of NSF and NIH shared instrumentation grants. We thank Dr. Joseph Ziller and Dr. John Greaves, Department of Chemistry, UC Irvine, for their assistance with X-ray and mass spectrometric analyses, and Dr. Nathan Crawford for helpful discussion with computational studies.

REFERENCES

1. Carr G, Tay W, Bottriell H, Andersen SK, Mauk AG, Andersen RJ. *Org. Lett.* 2009; 11:2996–2999. [PubMed: 19537768]
2. For recent reviews, see: Gardiner DM, Waring P, Howlett BJ. *Microbiology.* 2005; 151:1021–1032. [PubMed: 15817772] Jiang C-S, Guo Y-W. *Mini-*.
3. (a) Hollstein U. *Chem. Rev.* 1974; 74:625–652. (b) Graves, DE. *Sequence-specific DNA Binding Agents*. Waring, MJ., editor. RSC Publishing; Cambridge: 2006. p. 109-129. (c) Bolognese A, Correale G, Manfra M, Lavecchia A, Novellino E, Pepe S. *J. Med. Chem.* 2006; 49:5110–5118. [PubMed: 16913700] (d) Le Roes-Hill M, Goodwin C, Burton S. *Trends Biotechnol.* 2009; 27:248–258. and references therein. [PubMed: 19268377]
4. (a) Feng Y, Blunt JW, Cole ALJ, Munro MHG. *J. Nat. Prod.* 2004; 67:2090–2092. [PubMed: 15620259] (b) Usami Y, Yamaguchi J, Numata A. *Heterocycles.* 2004; 63:1123–1129. (c) Dong J-Y, He H-P, Shen Y-M, Zhang K-Q. *J. Nat. Prod.* 2005; 68:1510–1513. [PubMed: 16252916] (d) Zheng C-J, Kim C-J, Bae KS, Kim Y-H, Kim W-G. *J. Nat. Prod.* 2006; 69:1816–1819. [PubMed: 17190469] (e) Bertinetti BV, Rodriguez MA, Godeas AM, Cabrera GM. *J. Antibiot.* 2010; 63:681–683. [PubMed: 20823893] (f) Li L, Li D, Luan Y, Gu Q, Zhu T. *J. Nat. Prod.* 2012; 75:920–927. [PubMed: 22583079] (f) Wang F-Z, Huang Z, Shi X-F, Chen Y-C, Zhang W-M, Tian X-P. *Bioorg. Med. Chem. Lett.* 2012; 22:7265–7267. [PubMed: 23079524]

5. Many ETPs possess a hydroxyl substituent adjacent to the quaternary center in the pyrrolidine ring, as found in **1–3**. Molecules of this type readily undergo fragmentation when exposed to basic or acidic conditions or triphenylphosphine, see: Overman LE, Shin Y. *Org. Lett.* 2007; 9:339–341. and references therein. [PubMed: 17217299]
6. For selected studies reporting in vivo efficacy of ETPs, see: Waring P, Eichner RD, Müllbacher A. *Med. Res. Rev.* 1988; 8:499–524. [PubMed: 2461498] Vigushin DM, Mirsaidi N, Brooke G, Sun C, Pace P, Inman L, Moody CJ, Coombes RC. *Med. Oncol.* 2004; 21:21–30. [PubMed: 15034210] Kung AL, et al. *Cancer Cell.* 2004; 6:33–43. [PubMed: 15261140] Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. *Blood.* 2007; 109:2579–2588. [PubMed: 17090648] Lee Y-M, Lim J-H, Yoon H, Chun Y-S, Park J-W. *Hepatology.* 2011; 53:171–180. [PubMed: 21140472] Chaib H, Nebbioso A, Preber T, Castellano R, Garbit S, Restouin A, Vey N, Altucci L, Collette Y. *Leukemia.* 2012; 26:662–674. [PubMed: 21979880]
7. For aminophenoxazinones, see ref 3 and Estlin EJ, Veal GJ. *Cancer Treat. Rev.* 2003; 29:253–273. [PubMed: 12927566]
8. T988 A (7), an ETP co-isolated with **1-3**, was inactive against IDO, whereas synthetic cinnabarinic acid (**4**) was equipotent to **1-3**: see ref 1.
9. For an example of portmanteau inhibitors, see: Wang Z, Bennett EM, Wilson DJ, Salomon C, Vince R. *J. Med. Chem.* 2007; 50:3416–3419. [PubMed: 17608468]
10. For total syntheses of (+)-gliocladin C (**14**) and (+)-gliocladin C (**5**), see: DeLorbe JE, Jabri SY, Mennen SM, Overman LE, Zhang F-L. *J. Am. Chem. Soc.* 2011; 133:6549–6552. [PubMed: 21473649] For total syntheses of (+)-T988 C (**6**), (+)-gliocladin A (**8**) and structurally related ETPs, see: DeLorbe JE, Horne D, Jove R, Mennen SM, Nam S, Zhang F-L, Overman LE. *J. Am. Chem. Soc.* 2011; 133 dx.doi.org/10.1021/ja400315y.
11. For the total synthesis and stereochemical confirmation of (+)-gliocladin B (**11**), see: Boyer N, Movassaghi M. *Chem. Sci.* 2012; 3:1798–1803. [PubMed: 22844577]
12. For a review on total syntheses of ETPs, see ref 2c. For recent syntheses, see: Nicolaou KC, Totokotsopoulos S, Giguère D, Sun Y-P, Sarlah D. *J. Am. Chem. Soc.* 2011; 133:8150–8153. [PubMed: 21548595] Codelli JA, Puchlopek ALA, Reisman SE. *J. Am. Chem. Soc.* 2012; 134:1930–1933. [PubMed: 22023250] Nicolaou KC, Lu M, Totokotsopoulos S, Heretsch P, Giguère D, Sun Y-P, Sarlah D, Nguyen TH, Wolf IC, Smee DF, Day CW, Bopp S, Winzeler EA. *J. Am. Chem. Soc.* 2012; 134:17320–17332. [PubMed: 22978674]
13. For recent reviews, see Ley SV, Thomas AW. *Angew. Chem. Int. Ed.* 2003; 42:5400–5449. Evans G, Blanchard N, Toumi M. *Chem. Rev.* 2008; 108:3054–3131. [PubMed: 18698737] Hartwig JF. *Acc. Chem. Res.* 2008; 41:1534–1544. [PubMed: 18681463] Monnier F, Taillefer M. *Angew. Chem. Int. Ed.* 2009; 48:6954–6971. Surry DS, Buchwald SL. *Chem. Sci.* 2010; 1:13–31. [PubMed: 22384310] Surry DS, Buchwald SL. *Chem. Sci.* 2011; 2:27–50. [PubMed: 22432049] Fischer C, Koenig B. *Beilstein J. Org. Chem.* 2011; 7:59–74. [PubMed: 21286396] Rosen BM, Quasdorf KW, Wilson DA, Zhang N, Resmerita AM, Garg NK, Percec V. *Chem. Rev.* 2011; 111:1346–1416. [PubMed: 21133429]
14. For C–N cross-coupling of complex pyrrolidinoindolines, see Richard DJ, Schiavi B, Joullie MM. *Proc. Natl. Acad. Sci. U. S. A.* 2004; 101:11971–11976. [PubMed: 15141083] Foo K, Newhouse T, Mori I, Takayama H, Baran PS. *Angew. Chem. Int. Ed.* 2011; 50:2716–2719.
15. For other syntheses of **14**, see ref 5, 11, and Furst L, Narayanam JMR, Stephenson CRJ. *Angew. Chem. Int. Ed.* 2011; 50:9655–9659. Sun M, Hao X-Y, Liu S, Hao X-J. *Tetrahedron Lett.* 2013; 54:692–694.
16. (a) Ruan JW, Huang ZS, Huang JF, Du CJ, Huang SL, Shi Z, Fu LW, Gu CQ. *Chin. Chem. Lett.* 2006; 17:1141–1144. (b) Giurg M, Piekielska K, Gębala M, Ditkowski B, Wola ski M, Peczy ska-Czoch W, Mlochowski J. *Synth. Commun.* 2007; 37:1779–1789. and references therein.
17. Our early investigations focused on the N-arylation of indoline **17** with o-bromo(or iodo)benzoic acids and derivatives with Cu(I) and Pd(0) catalysts.¹³ Successful N-arylation was only observed using Cu(I) catalysts.
18. See Supporting Information for details of the preparation of **18**.
19. For an early example of CuTC in cross-couplings, see: Allred GD, Liebeskind LS. *J. Am. Chem. Soc.* 1996; 118:2748–2749. For CuTC in a related C–N cross-coupling, see Li G, Padwa A. *Org. Lett.* 2011; 13:3767–3769. [PubMed: 21696195]

20. For example, the corresponding mono Boc derivative of 18 was cross-coupled in less than 20% yield.
21. The relative and absolute configuration of 21a was secured by single crystal X-ray diffraction. These data have been deposited at The Cambridge Crystallographic Data Centre as entry CCDC 922842 and can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif.
22. For previous use of CuOAc in C–N cross-couplings, see: Bellina F, Calandri C, Cauteruccio S, Rossi R. *Eur. J. Org. Chem.* 2007:2147–2151. Kubo T, Katoh C, Yamada K, Okano K, Tokuyama H, Fukuyama T. *Tetrahedron*. 2008; 64:11230–11236.
23. For recent examples of direct introduction of methylthio substituents, at the α and α' -positions of dioxopiperazines, see: ref 2e, 10b, 11, 12a, 12c and Nicolaou KC, Giguère D, Totokotsopoulos S, Sun Y-P. *Angew. Chem. Int. Ed.* 2012; 51:728–732.
24. As observed computationally (and likely experimentally) for simple 2,5-dialkyl-3,6-di-(p-methoxybenzylthio)dioxopiperazines,²⁵ the lowest energy cis-disulfated stereoisomers of a are calculated (B3-LYP/def2-TZVP)²⁶ to be more stable by 2.5 kcal/mol (R = H) and 0.9 kcal/mol (R = Me).

25. Aliev AE, Hilton ST, Motherwell WB, Selwood DL. *Tetrahedron Lett.* 2006; 47:2387–2390.
26. (a) TURBOMOLE V6.3. Turbomole GmbH; Karlsruhe, Germany; 2011. <http://www.turbomole.com> (b) Treutler O, Ahlrichs R. *J. Chem. Phys.* 1995; 102:346–354.
27. See ref 5, and for the lability of aminophenoxazinones, see Bolognese A, Piscitelli C, Scherillo G. *J. Org. Chem.* 1983; 48:3649–3652.

Figure 1.
The plectosphaeroic acids and related metabolites.

Scheme 1.

Scheme 2.

Scheme 3.